Full-Time

Senior Data Architect

Updated on 8/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, PhD

Category
Data & Analytics (1)
Required Skills
Data Modeling
Data Governance

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A bachelor's degree with at least 8 years of experience, a master's degree with at least 6 years of experience, or a PhD in Computer Science, Data, Engineering, or a scientific discipline.
  • Demonstrated experience designing enterprise-scale data models and standards.
  • Experience working with scientific or research data domains.
  • Deep expertise in data modeling, metadata architecture, and semantic standards, with evidence of reuse at enterprise scale.
  • A strong grasp of FAIR principles and their practical application in research and analytics environments.
  • Architectural systems thinking involving tradeoffs across flexibility, governance, usability, and scalability.
  • The ability to influence without direct ownership of delivery, supported by strong written and verbal communication.
  • Domain literacy in scientific or research data, such as biology, chemistry, or therapeutic discovery.
Responsibilities
  • Define, evolve, and socialize FAIR-aligned canonical data models, metadata schemas, identifiers, and naming conventions across domains.
  • Own semantic interoperability strategies, including controlled vocabularies, reference data, and domain model alignment.
  • Establish architectural patterns that ensure data products are Findable, Accessible, Interoperable, and Reusable by default.
  • Define standards for versioning, provenance, lineage, and reuse contracts across the data lifecycle.
  • Partner with data governance, stewardship, and scientific domain leads to ensure standards are usable, adopted, and evolve pragmatically.
  • Lead architectural review and decision forums for schema, model, and standards changes.
  • Define and track FAIR maturity indicators, including metadata completeness, reuse readiness, and interoperability coverage.
  • Translate scientific and research workflows into durable architectural abstractions rather than bespoke implementations.
  • Provide architectural guidance and reference designs to data engineering teams implementing ingestion and transformation pipelines.
  • Influence tooling and platform capabilities to better support metadata, lineage, catalogs, and FAIR assessments.
  • Mentor engineers and technical leads on data modeling, semantics, and architectural reasoning.
  • Act as a thought leader for FAIR data architecture across SCIP and adjacent organizations.
  • Communicate architectural intent through design artifacts, documentation, and standards proposals.
  • Approve and evolve canonical data models, metadata standards, and architectural patterns.
  • Decide when and how FAIR standards evolve, including backward compatibility and deprecation.
  • Recommend tooling and platform investments to support FAIR adoption.
  • Influence, but do not directly commit, engineering capacity.
Desired Qualifications
  • Experience with FAIR, research data management, semantic modeling, or ontology-adjacent work.
  • Familiarity with metadata catalogs, lineage systems, and data governance frameworks.
  • Evidence of standard-setting and cross-organizational influence.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.05 billion, and guidance rose to $38.2-$39.4 billion.
  • Repatha sales jumped 37% in Q2 2026; Uplizna climbed 90%.
  • MariTide Phase 3 programs are enrolling now, with obesity readouts expected in 2027.

What critics are saying

  • FDA proposed Tavneos withdrawal on April 27, 2026 after data-integrity findings.
  • July 2026 Amgen settled a $74 million IRS-disclosure suit; tax litigation continues.
  • July 2026 layoffs hit Amgen again, signaling operating strain and portfolio pruning.

What makes Amgen unique

  • Repatha, Uplizna, and Imdelltra diversified Amgen beyond Enbrel and Prolia.
  • MariTide’s quarterly-or-sparser dosing targets obesity with lower treatment burden than weekly injectables.
  • Amgen’s 2025-2026 launches span cardiology, oncology, and rare disease globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

PR Newswire
Aug 4th, 2026
Amgen reports 10% revenue growth to $10.1B in Q2 2026, driven by 26% surge in six key growth products

Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.

Yahoo Finance
Jul 7th, 2026
Amgen wins Enbrel price cap reprieve as Class II recalls raise quality concerns

Amgen secured a preliminary injunction in early June 2026 blocking Colorado's proposed 70% price cap on Enbrel, its rheumatoid arthritis drug. The federal judge's decision preserves pricing flexibility for the legacy asset. However, the company initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the US due to foreign substances and manufacturing deviations. While not yet financially material, the recalls highlight ongoing operational risks. Amgen's investment case depends on its diversified portfolio offsetting pricing pressure and biosimilar competition. The company projects revenue of $40.1 billion and earnings of $9.9 billion by 2029, requiring 2.5% annual revenue growth. Current 2026 guidance stands at $37.1–$38.5 billion in revenue. The combination of pricing relief and quality concerns presents investors with a rebalanced risk-reward profile for the biotech company.

Yahoo Finance
Jun 30th, 2026
NEJM retracts trial behind Amgen's $459M Tavneos as FDA probes data changes

The New England Journal of Medicine has retracted the 2021 clinical trial that supported approval of Amgen's Tavneos, a treatment for ANCA-associated vasculitis that generated $459 million in sales last year. The retraction followed an FDA investigation revealing that results from nine patients were altered after the study database was finalised, whilst some researchers had been unblinded. The FDA alleges the original data showed no statistically significant difference between Tavneos and existing treatments, but subsequent changes made the drug appear more effective. The agency proposed withdrawing Tavneos from the US market in April, whilst European regulators have also recommended removal. Amgen, which acquired ChemoCentryx for $3.7 billion in 2022, continues selling Tavneos and has requested an FDA hearing. The company says it is engaging independent researchers to reanalyse the data.